Gland Pharma Limited (GLAND) — Board Meeting

1 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board reappointments and appointments effective June 15, 2026, including Vetter's five-year term and Keller's addition.

🔄 What Changed
Reappointment of Vetter for 5 years until 2031; appointment of Keller as Additional Director; resignation of Satyanarayana Murthy Chavali due to conflict of interest; committee realignments replacing Murthy with Vetter and Keller.

💡 Investor Takeaway
These changes strengthen board expertise and governance continuity while addressing conflict concerns, potentially supporting long-term stability.

Gland Pharma announced board changes effective June 15, 2026, reappointing Udo Jahannes Vetter as Independent Director for five years until 2031, appointing William Robert Keller as Additional Director, and accepting the resignation of Satyanarayana Murthy Chavali due to potential conflict of interest. C.S.N. Murthy's long-standing service was acknowledged, while Essaji Goolam Vahanvati joined a material subsidiary's board. Committee roles were restructured with Vetter assuming chairmanships and Keller appointed to key panels.

2 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board reappoints Vetter as Independent Director and appoints Keller as Additional Director amid governance reshuffle

🔄 What Changed
Vetter reappointed for second term; Keller appointed to Audit and Nomination & Remuneration Committees; Vetter assumes chairmanship of Risk and Stakeholders' Relationship Committees; Srinivas Sadu joins ESOP Compensation Committee

💡 Investor Takeaway
These governance changes strengthen board oversight and committee leadership continuity.

The board reappointed Udo Jahannes Vetter as Independent Director for a second term until 2031 and appointed William Robert Keller as an Additional Director effective June 15, 2026, following Satyanarayana Murthy Chavali's resignation due to conflict of interest. Essaji Goolam Vahanvati joined Gland Pharma International Pte. Ltd. as Director. Committee reshuffles placed Keller in the Audit and Nomination & Remuneration Committees, while Vetter took leadership of the Risk and Stakeholders' Relationship Committees, with Srinivas Sadu added to the ESOP Compensation Committee.

3 Board Meeting 🟡 Notable Neutral 📄 PDF

No summary available

📊 Stock Analysis — GLAND ✨ Ask AI About This